Mesothelioma: New concepts in diagnosis and management

Current Opinion in Pulmonary Medicine

Volumn 6, Issue 2, 2000, Pages 157-163

  Boylan, Alice M ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER STAGING; CANCER SURVIVAL; HUMAN; LUNG ADENOCARCINOMA; MESOTHELIOMA; OPEN LUNG BIOPSY; PLEURA MESOTHELIOMA; PLEURISY; REVIEW; SURVIVAL TIME;

EID: 0033822830     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200003000-00013     Document Type: Review

References (60)

1. Analysis of current trends in United States mesothelioma incidence
2. Diffuse malignant mesothelioma: Diagnosis and survival in 92 cases
3. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: A retrospective study of 332 patients
4. Non-asbestos-related malignant mesothelioma. A review
5. Latency of asbestos disease among insulation workers in the United States and Canada
6. Cancer risks due to asbestos and man-made fibers
7. Human mesotheliomas contain the simian virus-40 regulatory region and large tumor antigen DNA sequences
8. Simian virus 40 and pleural mesothelioma in humans
9. Contamination of poliovirus vaccines with simian virus 40 (1955-1963) and subsequent cancer rates
10. Pulmonary asbestos body counts and electron probe analysis of asbestos body cores in patients with mesothelioma: A study of 25 cases
11. Changing risk groups for malignant mesothelioma
12. Cigarette smoking, asbestos exposure and malignant mesothelioma
13. Malignant mesothelioma: The University of Minnesota experience
14. Multimodality therapy for malignant mesothelioma based on a study of natural history
15. Malignant pleural mesothelioma in the southwestern part of the Netherlands
16. Diffuse malignant mesothelioma
17. Pleural mesothelioma: Clinical features and therapeutic implications
18. Hyaluronic acid in 24 pleural fluids
19. Malignant pleural mesothelioma caused by environmental exposure to asbestos or erionite in rural turkey: CT findings in 84 patients
20. Malignant pleural mesothelicma: CT manifestations in 50 cases
21. Radiological features of diffuse mesothelioma
22. The role of computed tomography scanning in the initial assessment and the follow-up of malignant pleural mesothelioma
23. CT in differential diagnosis of diffuse pleural disease
24. A comparative study of mesothelioma and asbestosis using computed tomography and conventional chest radiography
25. MR imaging of malignant pleural mesothelioma
26. Usefulness of MR signal intensity in distinguishing benign from malignant pleural disease
27. Malignant pleural mesothelioma: Value of CT and MR imaging in predicting resectability
28. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography
29. Effusion cytology in the diagnosis of malignant epithelioid and biphasic pleural mesothelioma
30. Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 patients
31. CT-guided pleural biopsy in the diagnosis of malignant mesothelioma
32. Diagnosis of diffuse malignant mesothelioma: Experience of a US/Canadian mesothelioma panel
33. Immunopathologic and molecular studies as an aid to the diagnosis of malignant mesothelioma
34. Malignant mesothelioma of the pleura: Clinical aspects and symptomatic treatment
35. Immunoreactivity for Ber-EP4 in adenocarcinomas, adenomatoid tumors, and malignant mesotheliomas
36. Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma
37. WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis
38. Diffuse epithelial mesothelioma: A review of the ultrastructural spectrum
39. Detection of surfactant protein-A gene transcript in the cells from pleural effusion for the diagnosis of lung adenocarcinoma
40. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura: Experience in 29 patients
41. A proposed new international TNM staging system for malignant pleural mesothelioma
42. The importance of surgical staging in the treatment of malignant pleural mesothelioma
43. Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma
44. Resection margins, extrapleural nodal status, and cell type determine postoperative longterm survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients
45. Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of Cancer Experience
46. A review of chemotherapy trials for malignant mesothelioma
47. Cisplatin and gemcitabine treatment for malignant mesothelioma: A phase II study
48. Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma
49. Clinical features and current treatment of diffuse malignant pleural mesothelioma
50. The treatment of malignant mesothelioma of the pleura: Review of a 5-year experience, with special reference to radiotherapy
51. Altered fractionation of hemithorax irradiation for pleural mesotheioma and failure patterns after treatment
52. A Phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant mesothelioma
53. Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma
54. Successful immunochemotherapy for patients with malignant mesothelioma: Report of two cases
55. Intrapleural administration of interleukin 2 in pleural mesothelioma: A phase I-II study
56. Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma
57. Re-expression of p161NK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression
58. Cytokine gene therapy or infusion as treatment for solid human cancer
59. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: Results of a phase I clinical trial in malignant mesothelioma
60. Lovastatin induces apoptosis in malignant mesothelioma cells